WESTMINSTER, Colo., Might 03, 2021 (Globe NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medication tactic to creating genetically qualified therapies for cardiovascular illnesses, now introduced C. Jeff Dekker as its Main Economical Officer, effective Could 10, 2021, following Brian Selby’s planned departure just after 14 several years of service with the Firm.
Dr. Michael Bristow, ARCA’s President and Main Govt Officer commented: “We are delighted to welcome Jeff to ARCA as our Main Economical Officer. Jeff provides above 25 several years of biotech field and finance knowledge. I am self-confident he will be a robust CFO for ARCA. We believe his broad knowledge and capabilities in all features of finance, his elementary knowledge of our business enterprise and the market, and his powerful management, uniquely empower Jeff to support us continue to push our medical development and company strategies.”
Dr. Bristow commented more, “Over his 14 yrs of support, Brian has made invaluable contributions to ARCA. His partnership and direction directing our financial and accounting corporation presented a secure basis to assist advance our medical development programs. When we will miss out on his management, collaboration and perception, we would like him perfectly in his foreseeable future endeavors.”
Prior to joining ARCA, Mr. Dekker served in multiple roles of growing responsibility at GlobeImmune, Inc. from 2006 to 2021, like President, Vice President of Finance, and Senior Director, Finance and Controller. Just before becoming a member of GlobeImmune, Mr. Dekker held management positions in finance and accounting at personal application organizations due to the fact 1993, which include posts ranging from Company Controller to Vice President at Webroot Software program Inc., Requisite Technological innovation Inc. and NxTrend Technology Inc. Earlier in his career, Mr. Dekker worked at ITT Rayonier Port Angeles Pulp Division and at KPMG in Los Angeles. He attained a B.S. in accounting from Utah State College and is a licensed general public accountant.
About ARCA biopharma
ARCA biopharma is devoted to building genetically focused therapies for cardiovascular ailments via a precision medicine tactic to drug advancement. ARCA is building rNAPc2 as a opportunity cure for diseases triggered by RNA viruses, at first concentrating on COVID-19. The U.S. Food and drug administration has granted Rapid Track designation to the rNAPc2 growth program, at the moment in Stage 2 scientific tests. ARCA is also establishing GencaroTM (bucindolol hydrochloride), an investigational, pharmacologically one of a kind beta-blocker and moderate vasodilator, as a possible cure for atrial fibrillation in coronary heart failure patients. ARCA has identified popular genetic variations that it believes predict individual client response to Gencaro, giving it the potential to be the first genetically focused AF avoidance therapy. The U.S. Food and drug administration has granted the Gencaro advancement software Rapidly Monitor designation and a Specific Protocol Assessment (SPA) arrangement. For far more data, remember to visit www.arcabio.com or observe the Business on LinkedIn.
Protected Harbor Statement
This push launch incorporates “forward-searching statements” for purposes of the secure harbor supplied by the Non-public Securities Litigation Reform Act of 1995. These statements contain, but are not limited to, statements pertaining to the possible foreseeable future progress options for rNAPc2 and Gencaro, the predicted capabilities and characteristics of rNAPc2 and Gencaro, which includes the possible for genetic variants to predict particular person patient reaction to Gencaro, Gencaro’s possible to treat atrial fibrillation, rNAPc2’s likely to handle COVID-19, and the prospective for Gencaro to be the initially genetically targeted AF prevention therapy. These statements are based mostly on management’s present anticipations and require challenges and uncertainties. Precise success and effectiveness could differ materially from those people projected in the forward-wanting statements as a end result of many elements, such as, without having limitation, the challenges and uncertainties associated with: ARCA’s economic methods and no matter whether they will be sufficient to meet its business enterprise targets and operational necessities ARCA might not be ready to elevate enough money on acceptable conditions, or at all, to continue growth of rNAPc2 or Gencaro or to in any other case proceed operations in the upcoming results of before scientific trials may not be confirmed in upcoming trials the defense and current market exclusivity presented by ARCA’s mental assets dangers related to the drug discovery and the regulatory approval approach and, the influence of aggressive products and technological adjustments. These and other variables are recognized and explained in more detail in ARCA’s filings with the Securities and Exchange Fee, including with out limitation ARCA’s once-a-year report on Type 10-K for the 12 months finished December 31, 2020, and subsequent filings. ARCA disclaims any intent or obligation to update these forward-seeking statements.
Trader & Media Get hold of:
Derek Cole
720.940.2163
[email protected]
A photo accompanying this announcement is out there at https://www.globenewswire.com/NewsRoom/AttachmentNg/af496e97-20da-420a-bf93-e51b3a3ed740
